MindRank AI Powers Scientific Breakthroughs: Multiple High-Impact Publications in Top Journals Unlock New Pathways in Anti-Aging and Innovative Drug Discovery

Dec 25, 2025 17:30 CST Updated 17:30

MindRank

AI Drug Developer

Recently, MindRank (MindRank) inArtificial Intelligence Drug Discovery (AIDD)AndAnti-agingThe field has witnessed a gushing outbreak of scientific research achievements. The company and its cooperative teams have collectively produced6 articlesBreakthrough research papers consecutively published in the international authoritative academic journal "Science Advances"(IF: 15.5)、《Information Fusion》(IF: 12.5) And Acta Pharmaceutica Sinica B(IF: 14.6) Top-tier journal platforms.

These papers respectively cover the discovery of biological mechanisms,Three key dimensions: AI core algorithm innovation and clinical drug development strategies. This marks that MindRank's "AI + Biology" closed-loop platform has developed internationally leading source创新能力 in solving complex disease challenges such as Alzheimer's disease (AD).

"Top Algorithm in 'Information Fusion': A Major Leap in AI Molecular Graph Representation Accuracy (IF: 15.5)"

InIn the field of AI底层技术, MindRank collaborates with domestic universities such as Xiamen University, ranking first in the top journal in the field of artificial intelligence and information fusion.《Information Fusion》(IF: 15.5）Published a paper titled "Adaptive symmetry-based adversarial perturbation augmentation for molecular graph representations"Algorithm Research.

Precise molecular characterization isThe "Foundation" of AI Drug Discovery. To address the data sparsity and overfitting issues in existing models when handling complex molecular graphs, the MindRank AI team has proposed a novel adversarial perturbation enhancement algorithm based on adaptive symmetry.

Algorithm Innovation: The model introduces"Dual-fusion Attention Mechanism" (Dual-fusion attention) can more acutely capture the key features of chemical structures in the representation learning of molecular graphs.

Application Value: Experimental data shows that the algorithm significantly outperforms the current international best in key tasks such as molecular property prediction and activity screening.SOTA (State-of-the-art) Model. This means that MindRank's AI platform can achieve more accurate hits with less data when screening for new drugs, significantly shortening the drug discovery cycle.

《Science Advances》Major Publication: Revealing a New Mechanism of NAD+ Reversing AD Cognitive Deficits (IF: 12.5)

In the field of biological mechanism exploration, the MindRank team, in collaboration with institutions such as the University of Oslo in Norway, published in "Science》Sub-Journal, International Top Comprehensive Journal《Science Advances》(IF: 12.5)Published a paper titled“NAD+ reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C”Research Paper.

Alzheimer's Disease (The pathological mechanism of AD is extremely complex, and effective intervention targets have been lacking for a long time. This study, utilizing high-throughput sequencing and AI-assisted analysis, has revealed for the first timeCoenzyme I (NAD+)The key link with RNA alternative splicing.

Mechanism Breakthrough: Study Finds,NAD+ significantly corrects synaptic dysfunction in AD pathological states by regulating the alternative RNA splicing of the EVA1C gene.

Clinical Significance: This study demonstrated the restorationNAD+ levels can reverse neurofunctional deficits in AD models, providing a novel theoretical basis and high-value target for the development of AD drugs targeting RNA splicing regulation. This discovery is expected to fundamentally improve synaptic plasticity and cognitive function in AD patients, representing a significant advancement in the field of AD mechanism research.

《Acta Pharmaceutica Sinica B》Authoritative Review: Defining a New AI Paradigm for AD Drug Development (IF: 14.6)

In the field of pharmaceutical translation, MindRank collaboratesImperial College LondonandUniversity of Oslo, NorwayIn the top-tier journal of Zone 1 in the pharmaceutical field《Acta Pharmaceutica Sinica B》(IF: 14.6）Published a paper titled “Artificial intelligence in drug development for delirium and Alzheimer’s disease" Important Article.

FacingAlzheimer's Disease (AD）AndDeliriumDue to the high failure rate in drug development, the article systematically constructs an AI-powered full-process framework for CNS (Central Nervous System) drug research and development.

Industry Guidance: The article elaborates on how to utilize multimodalAI technology打通从靶点发现、晶体结构预测到临床患者分层的全链路瓶颈。

Strategic High Ground: The establishment of this high-score review demonstrates MindRank's deep accumulation and industry thought leadership in the field of neurological diseases, for ChinaCNS Drug Development Provides AI-Based Systematic Solutions.

In addition to the three high-impact top journals mentioned above, the MindRank team, in collaboration with the University of Cambridge and other universities, has also achieved significant results this year.《European Journal of Medicinal Chemistry》(IF: 6.0)Published the latest In silico modeling methods for PROTAC drug design in《Neurocomputing》(IF: 6.5)Published an article on the latest AI imaging method that utilizes residual diffusion models to rapidly generate synthetic immunofluorescence images from brightfield images; in《Aging and Disease》(IF: 6.9)Published research on the latest mechanism of NR1D1 inhibitors enhancing autophagy and mitophagy in Alzheimer's disease models.

FromFrom the underlying breakthrough of AI algorithms (Information Fusion), to the source innovation of disease mechanisms (Science Advances), and to the systematic implementation in pharmaceutical development (APSB), MindRank is accelerating the translation process from algorithms to clinical applications with its "trinity" of scientific research strengths, committed to bringing better treatment options to patients worldwide.

Thank youDynamic ResilienceProvided critical funding support for this project. As a selected project of its $60 million global anti-aging research funding initiative,MindRankJoin HandsUniversity of Oslo, Norway, University of Cambridge, UK, and Imperial College London, relying on the self-developed PharmKG platform and large-scale AI model technology, to jointly tackle the challenges of aging assessment and mechanism research. This funding will greatly accelerate the process of transforming AI technology into innovative anti-aging therapies, creating value for global health.

END

About MindRank

MindRank is a clinical-stageMindRank is an AI-driven biotech company dedicated to advancing AI for Science in the field of new drug discovery and leading paradigm shifts. Leveraging an AI platform that deeply integrates biology, structural biology, chemistry, and medicine, the company focuses on tackling "undruggable" targets, enhancing the efficiency and success rate of new drug discovery, with the aim of providing innovative therapies with greater clinical benefits for patients worldwide.

MindRank's Self-Developed WEE1/YES1 Dual Inhibitor Receives FDA Clinical Approval

AI Large Models Empower New Drug R&D Intelligence Insights, MindRank Completes Key Delivery of Merck China Knowledge Graph Project

MindRank Completes Over $20 Million Series A+ Financing to Accelerate Advancement of Innovative Drug Pipeline and AI Platform Commercialization

MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region

AI Large Language Models Accelerate the Development of Innovative Anti-Aging Therapies, MindRank Receives Support from Dynamic Resilience Fund

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai pr@mindrank.ai

Other: info@mindrank.ai